Streetbeat News

Products Services

HALO

Halozyme Therapeutics (NASDAQ: HALO) shares surged by 13.2% after the company raised its FY24 guidance, projecting significant growth in revenue, royalties, adjusted EBITDA, and non-GAAP earnings per share. The increase in guidance is attributed to a new European patent for its ENHANZE Drug Delivery Platform.

Portfolio Pulse from Nabaparna Bhattacharya

June 06, 2024 | 4:34 pm

WBD

Warner Bros. Discovery (WBD) is negotiating for a fourth NBA media-rights package, which could include regular-season and playoff games. This move aims to maintain TNT's long-standing relationship with the NBA and ensure the survival of its popular 'Inside the NBA' show. WBD is also dealing with significant debt and aims to avoid overpaying for the rights.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 4:31 pm

PLTR

Palantir Technologies shares are trading higher ahead of the company's AIPCon event.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 4:26 pm

PLTR

Palantir Technologies Inc (NYSE:PLTR) shares are trading higher as the company hosts its fourth AIPCon event, showcasing customer success with its AI platform. New customers will present their use cases, and Palantir will announce a new developer community. The stock has gained over 36% year-to-date, driven by strong commercial and government revenue growth.

Portfolio Pulse from Adam Eckert

June 06, 2024 | 4:25 pm

COIN

Coinbase Global has introduced the Coinbase Advanced Trade Go SDK, a new software development kit aimed at enhancing trading capabilities for developers.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 4:24 pm

BA

Boeing's Starliner spacecraft experienced a delay in docking with the International Space Station, holding outside the station for an extended period. This incident may impact investor confidence in Boeing's space ventures.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 4:17 pm

BMY

REPL

Replimune Group Inc (NASDAQ:REPL) reported positive topline results from its IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma, showing a 33.6% overall response rate. Bristol-Myers Squibb Co’s (NYSE:BMY) Nivolumab, sold as Opdivo, was used in the trial. REPL shares surged 28.40% following the news.

Portfolio Pulse from Vandana Singh

June 06, 2024 | 4:16 pm

JPM

USDTUSD

JPMorgan's recent report highlights the uncertain future of cryptocurrency regulation in the US, with potential opposition to CBDCs and non-compliant stablecoins. Key regulatory initiatives are stalled, creating a mixed outlook for the crypto industry.

Portfolio Pulse from Murtuza Merchant

June 06, 2024 | 4:15 pm

HOOD

Robinhood Inc. (NASDAQ:HOOD) has acquired Bitstamp, a major crypto exchange, to accelerate its vision of reorganizing the financial system through cryptocurrencies. The acquisition has been praised by industry experts as a bold and significant move, despite Robinhood recently receiving a wells notice from the SEC. The deal is expected to have long-term implications for the fintech sector and the broader crypto market.

Portfolio Pulse from Murtuza Merchant

June 06, 2024 | 4:11 pm

LLY

Eli Lilly's Alzheimer's drug, donanemab, will face an FDA advisory committee vote on June 10 to assess its benefit-risk profile based on Phase 3 study data. The study showed statistically significant results in reducing cognitive decline and improving daily function in Alzheimer's patients.

Portfolio Pulse from Vandana Singh

June 06, 2024 | 4:07 pm